Lipocine Inc.
LPCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001535955
In the last 90 days, Lipocine Inc. insiders filed 1 open-market purchase and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Lipocine Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 22 | 26 | +4 |
| Shares | 529.3K | 1.63M | +1.10M (+207.9%) |
| Value | $1.51M | $13.1M | +$11.6M (+765.5%) |
New holders (8)
Institutions that held Lipocine Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Squadron Capital Management LLC | 530,000 | $4.26M | 1.90% |
| Diadema Partners LP | 260,939 | $2.10M | 1.25% |
| Ikarian Capital, LLC | 199,542 | $1.60M | 0.21% |
| Persistent Asset Partners Ltd | 70,576 | $566.7K | 0.27% |
| Boothbay Fund Management, LLC | 54,893 | $440.8K | 0.01% |
| Ameriprise Financial Inc | 16,104 | $129.3K | 0.00% |
| Jane Street Group, LLC | 10,574 | $84.9K | 0.00% |
| HighMark Wealth Management LLC | 100 | $803 | 0.00% |
Sold out (4)
Institutions that held Lipocine Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Citadel Advisors LLC | 14,247 | $40.7K |
| Barclays PLC | 9,412 | $26.8K |
| Tower Research Capital LLC (TRC) | 1,170 | $3.33K |
| Citigroup Inc | 3 | $9 |